Combining MK2206 with gefitinib has also been shown to be successful in EGFR expressing malignant glioma cells, where combined therapy resulted in a synergistic increase in apoptosis and autophagy in vitro, and increased anti-tumor activity in vivo [36]. This evidence concerns the gene EGFR and neoplasm.